Skip to main content
. Author manuscript; available in PMC: 2011 Oct 27.
Published in final edited form as: Cancer Res. 2010 May 1;70(9):3687–3696. doi: 10.1158/0008-5472.CAN-09-3931

Figure 3.

Figure 3

Therapeutic efficacy of sustained EphA2-siRNA-DOPC delivery by S1MP. Nude mice were injected i.p. with SKOV3ip1 or HeyA8 cells and randomly allocated to one of six treatment groups (n = 10): (a) saline, (b) S1MP, (c) nonsilencing control siRNA-DOPC, (d) S1MP-nonsilencing control-siRNA-DOPC, (e) EphA2-siRNA-DOPC, (f) S1MP-EphA2-siRNA-DOPC. SiRNA-DOPC was i.v. injected biweekly at a dose of 5 µg siRNA. S1MP-EphA2-siRNA-DOPC was injected in a single administration in 3 wks at a dose of 15 µg siRNA. The mice were injected with saline biweekly in the rest of treatment period. When control animals (saline- and nonsilencing siRNA–treated mice) began to appear moribund (4–5 wks after cell injection), all animals in an experiment were sacrificed and mouse weight, tumor weight (wt), tumor number, ascites volume, and tumor location were recorded. Columns, mean tumor weight from SKOV3ip1 (A) or HeyA8 cells (B); bars, SD.